CollPlant narrowed net loss in 2025 as AbbVie milestone drives revenue surge
Compartilhar
CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetic medicine company developing innovative technologies based on its proprietary plant-derived recombinant human collagen (rhCollagen), today reported financial results for the full year ended December 31, 2025.
